谢俊峰+胡云淑

[摘要]目的 探討硫糖铝片联合双歧杆菌三联活菌胶囊治疗腹泻型肠易激综合征的临床效果。方法 选取我院2011年2月～2016年2月收治的220例腹泻型肠易激综合征患者作为研究对象，随机分为对照组和实验组，各110例。对照组口服双歧杆菌三联活菌胶囊；实验组在对照组的基础上加服硫糖铝片，连续治疗6个周期，停药4周后，观察两组的临床疗效。结果 实验组的总有效率为92.73%，高于对照组的80.91%，差异有统计学意义（P<0.05）。实验组治疗后的异常临床症状明显缓解，与对照组比较差异有统计学意义（P<0.05）。两组的不良反应发生率比较，差异无统计学意义（P>0.05）。实验组在1个月和2个月时的复发率为0.91%、4.55%，显著低于对照组的5.45%、12.73%，差异有统计学意义（P<0.05）。结论 采用硫糖铝片联合双歧杆菌三联活菌胶囊治疗腹泻型肠易激综合征安全有效，患者的临床症状能得到明显改善，且不良反应较少，值得临床推广应用。

[关键词]硫糖铝片；双歧杆菌三联活菌胶囊；腹泻型肠易激综合征；临床疗效

[中图分类号] R574 [文献标识码] A [文7章编号] 1674-4721（2017）05（b）-0109-03

Clinical effect of Sucralfate Tablets combined with Bifidobacterium Triple Viable Capsule in the treatment of diarrhea type irritable bowel syndrome

XIE Jun-feng HU Yun-shu

Department of Gastroenterology，Traditional Chinese Medicine Hospital of Fuling District in Chongqing City，Chongqing 408000，China

[Abstract]Objective To explore the clinical effect of Sucralfate Tablets combined with Bifidobacterium Triple Viable Capsule in the treatment of diarrhea type irritable bowel syndrome.Methods 220 patients with diarrhea type irritable bowel syndrome who were treated in our hospital from February 2011 to February 2016 were selected and randomly divided into the experimental group and the control group，110 cases in each group.The control group was treated with Bifidobacterium Triple Viable Capsule，the experimental group was treated with Sucralfate Tablets on the basis of the control group.The two groups were treated for 6 cycles，and after 4 weeks of withdrawal，the clinical efficacy of the two groups was observed.Results The total effective rate of the experiment group was 92.73%，which was higher than 80.91% of the control group，with significant difference （P<0.05）.The abnormal clinical symptoms after treatment in the experimental group were significantly relieved，compared with the control group，the difference was statistically significant （P<0.05）.There was no significant difference in the incidence rate of adverse reactions between the two groups （P>0.05）.The recurrence rate at 1 months and 2 months of the experimental group was 0.91% and 4.55%，which was significantly lower than that of the control group （5.45% and 12.73%），with significant difference （P<0.05）.Conclusion Sucralfate Tablets combined with Bifidobacterium Triple Viable Capsule in the treatment of diarrhea type irritable bowel syndrome is safe and effective，the clinical symptoms of the patients can be significantly improved，and the adverse reactions is less，and it is worthy of clinical promotion and application.

[Key words]Sucralfate Tablets；Bifidobacterium Triple Viable Capsule；Diarrhea type irritable bowel syndrome；Clinical curative effect

肠易激综合征（irritable bowel syndrome，IBS）是临床中较为常见的胃肠功能紊乱性疾病之一，临床主要表现为腹痛、腹胀、排便习惯改变及大便形态异常或黏液便等，症状持续存在或间歇发作，腹泻型是其最常见的类型[1-2]。对于腹泻型IBS的治疗，临床上缺乏特效药物，有研究显示，双歧杆菌三联活菌胶囊能够缓解腹泻型IBS的临床症状，但停药后容易复发[3-4]。有资料显示，硫糖铝片具有收敛止泻、保护胃肠黏膜的作用，因此，本院采用双歧杆菌三联活菌胶囊联合硫糖铝片对近五年收治的220例腹泻型IBS进行治疗，取得了较好的效果，现报道如下。

1资料与方法

1.1一般资料

选取我院2011年2月～2016年2月收治的220例腹泻型IBS患者，其中，男性123例，女性97例；年龄26～81岁，平均（49.27± 3.45）岁；病程为11～34个月；腹痛及腹部不适211例，排便频率异常217例，粪便性状异常214例。……